The company that applied for authorisation is Vivus BV. On 18 October 2012, the Committee for Medicinal Products for Human Use ( CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Qsiva, intended for the treatment of obesity. The applicant requested a re-examination of the opinion. Alli® - 1 x abnormal liver function tests SIGN 115 - Feb 2010 A grade recommendation.MHRA - 137 suspected hepatic ADRs - 2 fatal.20 reports linked to alli® (UK April 2009).1,295 suspected adverse drug reactions (ADRs).MHRA monitoring since licensed in 1998.NICE and the Scottish Intercollegiate Guidelines Network (SIGN) provide guidance for multicomponent lifestyle weight management, based on the severity of obesity and the. In the UK, people with obesity primarily access weight loss interventions through primary care services 24, 25, 26 or by self‐referral to commercial slimming organizations.